

1 **Efficacy and safety of *Andrographis paniculata* extract in patients with**  
2 **mild COVID-19: A randomized controlled trial**

3  
4 Kulthanit Wanaratna<sup>a</sup>, Pornvimol Leethong<sup>b</sup>, Nitapha Inchai<sup>a</sup>, Wararath Chueawiang<sup>a</sup>,  
5 Pantitra Sriraksa<sup>a</sup>, Anutida Tabmee<sup>a</sup>, Sayomporn Sirinavin<sup>c</sup>

6  
7 <sup>a</sup>Department of Thai Traditional and Alternative Medicine, Ministry of Public Health,  
8 Thailand

9 <sup>b</sup>Samutprakarn Hospital, Ministry of Public Health, Thailand

10 <sup>c</sup>Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine  
11 Ramathibodi Hospital, Mahidol University, Thailand

12

13

14

15 Corresponding author:

16 Kulthanit Wanaratna, MD.

17 Department of Thai Traditional and Alternative Medicine

18 Ministry of Public Health, Thailand

19 E-mail: kulthanitw@gmail.com

20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

## ABSTRACT

**Objectives:** To assess the efficacy and safety of *Andrographis paniculata* extract (APE) in adults with mild COVID-19.

**Methods:** Sixty-three adults aged 18-60 years, without co-morbidity, with laboratory-confirmed mild COVID-19, were randomized 1:1 to receive APE (60 mg andrographolide, t.i.d, for 5 days) or placebo within 24 hours after admission, plus standard supportive care. The outcomes were clinical recovery rates by Day 5 using self-assessment scores, pneumonia by chest X-rays, nasopharyngeal SARS-CoV-2 detection by rRT-PCR on Day 5, changes of serum CRP levels, and adverse drug reactions. Chest X-rays and blood tests for CRP, liver and renal function, were performed on Days 1, 3, and 5.

**Results:** Baseline characteristics of patients in the APE-treatment (n=29) and placebo-control (n=28) groups were comparable. None had self-assessment scores showing complete clinical recovery by Day 5. Pneumonia occurred in 0/29 (0%) versus 3/28 (10.7%), (p=0.112). On Day 5, patients with SARS-CoV-2 detection were 10/29 (34.5%) versus 16/28 (57.1%), (p=0.086); patients with CRP >10 mg/L were 0/29 (0%) versus 5/28 (17.9%), (p=0.023), for APE-treatment and placebo-control groups, respectively. All three patients with pneumonia had substantially rising serum CRP; and high CRP levels on Day 5. None had evidence of hematologic, hepatic or renal impairment.

**Conclusion:** Even though the study was limited by small sample size, our findings suggested promising efficacy and safety of the APE-treatment regimen in adults with mild COVID-19. Further studies, with adequate power to assure these findings, are required.

**Keywords:** *Andrographis paniculata*; COVID-19; SARS-CoV-2; randomized controlled trial; C-reactive protein; pneumonia

43

## Introduction

44           Coronavirus disease 2019 (COVID-19), caused by the novel severe acute  
45 respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic of  
46 the highest priority (World Health Organization, 2021). Clinical spectrum of the disease is  
47 categorized into asymptomatic, mild, moderate, severe, and critical illness. About 80% of  
48 cases are classified as asymptomatic and mild (fever or upper respiratory tract symptoms,  
49 malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste or smell, but  
50 without pneumonia), or moderate (pneumonia, with oxygen saturation  $\geq 94\%$  on room air).  
51 Mild COVID-19 may worsen to moderate and severe disease, while pneumonia is the  
52 primary indicator of more severe disease progression alongside multiple organ  
53 dysfunction or failure (Wu and McGoogan, 2020; National Institute of Health USA, 2021).

54           Predictors of a worse outcome in COVID-19 patients include host factors (e.g.,  
55 gender, age, co-morbidities), disease characteristics (Wu and McGoogan, 2020; National  
56 Institute of Health USA, 2021), and laboratory parameters such as C-reactive protein  
57 (CRP), which is an inflammatory marker (Mueller et al., 2020; Potempa et al., 2020;  
58 Wang, 2020; Stringer et al., 2021). In normal healthy individuals, baseline CRP levels in  
59 the blood are reported to be less than 10 mg/L (World Health Organization, 2014; Wang,  
60 2020). The main mechanisms of disease progression in COVID-19 are intracellular viral  
61 replication causing cell lysis or cell death, and hyperactivation of immune responses  
62 contribute to widespread hyperinflammation (van Eijk et al., 2021). In addition to  
63 symptomatic management of patients with COVID-19, a therapeutic drug that would limit  
64 the course of infection is urgently needed.

65 *Andrographis paniculata* (Burm.f.) Nees is an annual herb native to the Indian  
66 subcontinent and widely introduced, naturalized, and cultivated in Southeast Asia and  
67 China (Kew Science, 2019). It is one of the commonly used medicinal plants in Indian  
68 Ayurvedic medicine, Chinese and Thai traditional medicines, for the treatment of acute  
69 upper respiratory tract infection and diarrhea (National Drug Committee, Thailand 2000;  
70 The State Pharmacopoeia Commission of the People's Republic of China, 2015;  
71 Banerjee et al., 2021). Its name in Thai is Fa Thalai Chon. The main constituent of *A.*  
72 *paniculata* is andrographolide which is a bioactive diterpene lactone. The therapeutic  
73 efficacy of *A. paniculata* is due to its various pharmacological activities, i.e., antiviral, anti-  
74 inflammatory, antipyretic, and immune regulation activities (Dai et al., 2019; Hossain et  
75 al, 2021). The adverse effects include headache, fatigue, allergic reactions, nausea,  
76 diarrhea, and mild hypotension, which are uncommon; while more severe adverse effects,  
77 although very rare, are urticaria or anaphylaxis (Thamlikitkul et al., 1991; Suriyo et al,  
78 2017; Worakunphanich et al., 2021).

79 *In silico* studies revealed that andrographolide is an inhibitor of the main protease  
80 of SARS-CoV-2 which leads to prevention of viral replication (Murugan et al., 2020; Shi  
81 et al., 2020; Enmozhi et al., 2021; Hiremath et al., 2021). Furthermore, *in vitro* study also  
82 demonstrated that it acts on SARS-CoV-2 by preventing viral replication in cells,  
83 especially in late phase of viral life cycle. (Phumiamorn S, 2020; Sa-Ngiamsumtorn et al.,  
84 2021). The treatment effects of APE were explored in a small group (n=6) of mild COVID-  
85 19 volunteers; clinical improvement and SARS-CoV-2 reduction were detected.

86 Therefore, this randomized, double-blind, placebo-controlled trial was conducted  
87 to determine the clinical and virological efficacy, and safety of oral *A. paniculata* extract

88 among adults with mildly symptomatic SARS-CoV-2 infection. Additionally, we explored  
89 the role of serum CRP in the prediction of disease progression in mild COVID-19.

## 90 **Patients and Methods**

91 The study was conducted from December 2020 to March 2021, during the second  
92 COVID-19 epidemic wave in Thailand. During that period of time, anyone who tested  
93 positive for SARS-CoV-2, from nasopharyngeal swabs for real-time reverse transcription  
94 polymerase chain reaction (rRT-PCR) test, were promptly admitted to state quarantine  
95 hospitals. Samut Prakan Hospital and Nakhon Pathom Hospital, two state quarantine  
96 hospitals in central Thailand, were our study sites.

### 97 **Patients**

98 The patient inclusion criteria were (1) age 18–60 years; with (2) diagnosis of  
99 SARS-CoV-2 infection by positive rRT-PCR test; (3) being admitted to the hospitals within  
100 72 hours of illness; (4) presence of any signs and symptoms of mild COVID-19 (e.g.,  
101 fever, cough, sore throat, malaise, headache, and diarrhea); and (5) not having signs and  
102 symptoms of pneumonia or abnormal chest imaging. Patients were excluded if they (1)  
103 had any underlying medical conditions that increased the risk of severe COVID-19; (2)  
104 had any conditions for which using *A. paniculata* should be avoided, i.e., history of allergy  
105 to *A. paniculata*, taking antihypertensive or anticoagulant drugs, pregnancy or breast-  
106 feeding; or (3) were receiving any antiviral drug. On admission to the study hospitals, the  
107 inclusion and exclusion criteria were verified. Patients were informed about the study project  
108 and those interested in study participation were requested to sign informed consent.

109

110 **Study treatment**

111 The standardized alcoholic extract of the aerial part of *A. paniculata* (APE, AP  
112 extract) was used. Both APE and placebo capsules were produced by Thai Herbal  
113 Products Co., Ltd, Thailand, and both were indistinguishable. Each capsule of APE  
114 contains 20 mg of andrographolide. The patients received either oral APE or placebo,  
115 within 24 hours after admission (Day 1 of clinical trial), in addition to standard supportive  
116 care following the national clinical practice guideline. The APE-treatment patients  
117 received 3 capsules (60 mg. andrographolide) of APE while the placebo-control patients  
118 received 3 capsules of placebo, 3 times a day (t.i.d.), for 5 days.

119 **Outcome assessment**

120 The primary outcomes were complete clinical recovery rates by Day 5. The  
121 secondary outcomes included pneumonia development during the course of illness,  
122 SARS-CoV-2 detection, serum CRP levels, and adverse drug reactions. Clinical recovery  
123 was self-assessed by the patients using visual analog scale (VAS) scores. Chest X-rays  
124 were assessed on Days 1, 3, and 5 of the clinical trial. Additional chest X-rays were  
125 performed for those without abnormal chest X-rays by Day 5, who had progression of  
126 respiratory symptoms. Nasopharyngeal swabs were performed on Day 5 for the detection  
127 of SARS-CoV-2 by rRT-PCR. Venous blood specimens were collected on Days 1, 3, and  
128 5 for complete blood count, blood urea nitrogen and creatinine, aspartate  
129 aminotransferase and alanine aminotransferase, and CRP. Suspected clinical adverse  
130 effects of drugs were recorded.

131

132

### 133 **Sample size**

134           Sample size was calculated from the primary outcome with assumption that the  
135 duration of symptoms in mild COVID-19 was about 5 days and that the AP-treatment  
136 would cause 2-day decrease in duration. This led to an estimated sample size of 26  
137 participants per group to provide type I error of 5% and type II error of 20%. The intended  
138 sample size was adjusted to 32 participants per group to compensate for possible drop-  
139 out.

### 140 **Randomization and blinding**

141           The 1:1 randomization was prepared by a central researcher before participant  
142 enrollment, by block randomization with a block size of six using a randomization  
143 software. The randomization codes were labelled on APE or placebo packages which  
144 were physically indistinguishable; each package contained 45 capsules of APE or placebo  
145 for 5-day treatment of individual patients. The study hospitals were provided with code-  
146 labelled packages of APE or placebo. Each new participant was assigned the code on  
147 the received drug package. The randomization code was kept secret from the clinic and  
148 the participating investigators, and the code was revealed at the end of the study for  
149 analysis.

### 150 **Statistical analysis**

151           Data were described by mean with standard deviation (mean  $\pm$  SD) or frequency  
152 (%), and compared between groups by Student t-test for continuous data, Chi-square test  
153 or Fisher exact test for categorical data. All analyses were performed by STATA version  
154 16.0, and p-value <0.05 was considered as being statistically significant.

155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177

## Results

Fifty-seven of the 63 enrolled patients completed the study, 29 patients in the APE-treatment group and 28 patients in the placebo-control group. Three patients of each group withdrew during the study, due to unwillingness for further blood testing (2 control, 2 APE-treatment) and unpleasant symptoms (1 palpitation in control, and 1 diarrhea in APE-treatment); while none of them developed pneumonia. The baseline characteristics (age, gender, body mass index, and CRP level on enrollment) were comparable between the 2 groups (Table1).

None of the participants had complete clinical recovery by Day 5 as determined by patient self-assessed VAS scores, and further assessment was not performed according to the protocol. Table 2 showed the numbers of patients with pneumonia, Day-5 detection of nasopharyngeal SARS-CoV-2, and CRP levels >10 mg/L in the two groups. None of the patients in the APE-treatment group, but 3 patients in the placebo-control group developed pneumonia (on Days 6-7), being 0/29 (0%) versus 3/28 (10.7%), ( $p=0.112$ ). On Day 5, SARS-CoV-2 was detected from nasopharyngeal swab in 10/29 (34.5%) patients of the APE-treatment group, and 16/28 (57.1%) patients of the placebo-control group, ( $p=0.086$ ).

None of the APE-treatment group had CRP >10 mg/L during the 5-day study period. On admission, 2 patients in the placebo-control group had high CRP levels (18.3 and 18.4 mg/L), and one who had rising CRP levels developed pneumonia while another with steady CPR levels did not. On Day 5, the proportions of patients with CRP >10 mg/L were 0/29 (0%) in APE-treatment group, and 5/28 (17.9%) in placebo-control group, ( $p=0.023$ ). Three patients who had pneumonia had substantially rising serum CRP on



178 Day 3 and high CRP of 13.9, 20.7, and 21.0 mg/L on Day 5. In addition, 2 patients in the  
179 placebo-control group had rising CRP and high CRP of 16.0 and 16.1 mg/L on Day 5, but  
180 did not have pneumonia.

181 Abnormal symptoms as possible AP adverse effects were found in 2 patients in  
182 the APE-treatment group, and both were mild and self-limited gastrointestinal tract  
183 symptoms (1 diarrhea), and one patient in the placebo-control group had palpitation.  
184 None of the patients in both groups had laboratory evidence of hematologic, hepatic or  
185 renal function impairment.

## 186 Discussion

187 The study of the efficacy of APE-treatment on the primary outcome, as clinical  
188 recovery rates by Day 5, could not give relevant information. However, our study suggests  
189 that the regimen of APE treatment (oral 60 mg of andrographolide, t.i.d., for 5 days) given  
190 early to adults with mild COVID-19, without risk for severe COVID-19 by host factors, has  
191 promising efficacy on mild COVID-19, though the sample size is too small to detect  
192 statistically significant difference of outcomes. The study suggests a tendency of risk  
193 reduction of pneumonia, more rapid SARS-CoV-2 clearance, and inflammation  
194 suppression. The potential treatment benefit of APE on COVID-19 is likely to be the result  
195 of the anti-SARS-CoV-2 and anti-inflammatory activities of andrographolide and its  
196 derivatives. Adverse effects from the treatment were found uncommon and benign.

197 A recent comprehensive review on antimicrobial pharmacology, clinical safety, and  
198 efficacy of *Andrographis paniculata*, demonstrated its high potential for effective and safe  
199 COVID-19 treatment, and there was a need for clinical evidence (Hossain et al., 2021).  
200 This study was performed on orally-administered APE in mild COVID-19 patients. A recent

201 study from China on injectable andrographolide (Xiyanping in Chinese) in mild to moderate  
202 COVID-19 patients, demonstrated significant reduction of the time to cough relief, fever  
203 resolution and virus clearance, and less patients experienced disease progression to the  
204 severe stage. (Zhang et al., 2021).

205 The second epidemic wave of SARS-CoV-2 in Thailand lasted between December  
206 2020 and March 2021, the duration which covered the study period. Using the whole  
207 genome sequencing, it was found that approximately 90% of the strains, circulating in the  
208 study area during that period, belonged to the B.1.36.16 lineage (COVID-19 Network  
209 Investigations Alliance, 2021). Considering that the treatment effects of andrographolide  
210 may vary with different SARS-CoV-2 strains, further exploration is therefore needed.

211 Three patients who had pneumonia had substantially rising serum CRP on Day 3  
212 and high CRP of 13.9, 20.7, and 21.0 mg/L on Day 5. These findings of this study on  
213 serum CRP levels in mild COVID-19 patients agree with the previous retrospective study  
214 in 27 adults in the early stage of COVID-19 that CRP levels were low in mild disease and  
215 increased with disease progression (Wang, 2020). A study reported that increasing CRP  
216 levels during the first 48-to-72 hours of hospitalization was a better predictor of respiratory  
217 deterioration than initial CRP levels, while steady CRP levels were observed in patients  
218 whose condition remained stable (Mueller et al., 2020).

219 The proportions of the 3 secondary outcomes (pneumonia, viral detection, CRP)  
220 in the 2 compared groups of this trial suggested benefit of APE-treatment in mild COVID-  
221 19. A statistically non-significant difference ( $p \geq 0.05$ ) in this underpowered study does not  
222 imply that the treatment is not clinically effective (Tsang R, 2009).

223

224  
225  
226  
227  
228  
229  
230  
  
231  
232  
233  
234  
235  
236  
237  
  
238  
239  
240  
241  
242  
243  
244  
245

## Conclusions

This double-blind RCT, in adults with mild COVID-19 and without risk factors for severe disease, suggested promising effects of the oral APE-treatment regimen on the prevention of pneumonia, shortening of viral shedding period, and inflammatory suppression. Adverse drug reactions were mild, self-limited, and uncommon. The study was limited by the small sample size. Further studies, with adequate power to assure conclusions, are required.

## Acknowledgments

The authors gratefully acknowledge the study team, at Samut Prakan Hospital and Nakhon Pathom Hospital, who involved in this study; the Department of Medical Science, Ministry of Public Health (MOPH), for virological study; Dr. Marut Jirasetsiri and Dr. Amporn Benjaponpitak, Department of Thai traditional and Alternative Medicine, MOPH, for their full encouragement and support. We would like to thank Stephen John Pinder and Dr. Anchalee Chuthaputti for conducting a language review on this manuscript.

**Financial support.** This research project was supported by Thai Traditional Medical Knowledge Fund.

**Potential conflicts of interest.** The authors have no conflicts of interest to declare.

**Ethics approval and consent to participate.** Ethical approval was obtained from the Ethics Committee for Research in Human Subjects in the Fields of Thai Traditional and Alternative Medicine (No.12-2563). All participants gave written informed consent.

246

## References

- 247 [1] Banerjee S, Kar A, Mukherjee PK, Haldar PK, Sharma N, Katiyar CK.  
248 Immunoprotective potential of Ayurvedic herb Kalmegh (*Andrographis paniculata*)  
249 against respiratory viral infections - LC-MS/MS and network pharmacology analysis.  
250 Phytochem Anal. 2021;32:629-39. <https://doi.org/10.1002/pca.3011>.
- 251 [2] COVID-19 Network Investigations (CONI) Alliance. Genomic epidemiology of novel  
252 coronavirus - Thailand-focused subsampling. Available from:  
253 [https://nextstrain.org/community/fai-k/coni/Thailand?c=pango\\_lineage&l=scatter](https://nextstrain.org/community/fai-k/coni/Thailand?c=pango_lineage&l=scatter).  
254 (Accessed: 22 July 2021).
- 255 [3] Dai Y, Chen SR, Chai L, Zhao J, Wang Y, Wang Y. Overview of pharmacological  
256 activities of *Andrographis paniculata* and its major compound andrographolide.  
257 Crit Rev Food Sci Nutr. 2019; 59: S17-S29.  
258 <https://doi.org/10.1080/10408398.2018.1501657>.
- 259 [4] Enmozhi SK, Raja K, Sebastine I, Joseph J. Andrographolide as a potential inhibitor  
260 of SARS-CoV-2 main protease: an in silico approach. J Biomol Struct Dyn. 2021;39:  
261 3092-3098. <https://doi.org/10.1080/07391102.2020.1760136>.
- 262 [5] Hiremath S, Kumar HDV, Nandan M, Mantesh M, Shankarappa KS,  
263 Venkataravanappa V, et al. In silico docking analysis revealed the potential of  
264 phytochemicals present in *Phyllanthus amarus* and *Andrographis paniculata*, used  
265 in Ayurveda medicine in inhibiting SARS-CoV-2. 3 Biotech. 2021;11: 44.  
266 <https://doi.org/10.1007/s13205-020-02578-7>

- 267 [6] Hossain S, Urbi Z, Karuniawati H, Mohiuddin RB, Moh Qrimida A, Allzrag AMM, et  
268 al. *Andrographis paniculata* (Burm. f.) Wall. ex Nees: An updated review of  
269 phytochemistry, antimicrobial pharmacology, and clinical safety and efficacy. *Life*.  
270 2021;11(4):348. <https://doi.org/10.3390/life11040348>
- 271 [7] Kew Science. Plant of the World Online. *Andrographis paniculata* (Burm.f.) Nees.  
272 <http://www.plantsoftheworldonline.org/taxon/urn:lsid:ipni.org:names:45226-1>.  
273 (Accessed: 24 June 2021).
- 274 [8] Mueller AA, Tamura T, Crowley CP, DeGrado JR, Haider H, Jezmir JL, et al.  
275 Inflammatory biomarker trends predict respiratory decline in COVID-19 patients.  
276 *Cell Rep Med*. 2020;1(8),100144. <https://doi.org/10.1016/j.xcrm.2020.100144>.
- 277 [9] Murugan NA, Pandian CJ, and Jeyakanthan J. Computational investigation on  
278 *Andrographis paniculata* phytochemicals to evaluate their potency against SARS-  
279 CoV-2 in comparison to known antiviral compounds in drug trials. *J Biomol Struct*  
280 *Dyn*. 2020;16:1-12. <https://doi.org/10.1080/07391102.2020.1777901>.
- 281 [10] National Drug Committee. National list of essential drugs 1999 (List of herbal  
282 medicine products). Bangkok: Agricultural cooperative federation of Thailand. 2000.
- 283 [11] National Institute of Health, USA. Clinical Spectrum of SARS-CoV-2 Infection.  
284 <https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/>. 2021  
285 (Accessed: 13 June 2021).
- 286 [12] Phumiamorn S, Sapsutthipas S, Pruksakorn P, Trisiriwanich S. *In vitro* study on  
287 antiviral activity of *Andrographis paniculata* against COVID-19.  
288 <https://www3.dmsc.moph.go.th/en/>. 2020 (Accessed: 13 June 2021).

- 289 [13] Potempa LA, Rajab IM, Hart PC, Bordon J, Fernandez-Botran R. Insights into the  
290 Use of C-Reactive Protein as a Diagnostic Index of Disease Severity in COVID-19  
291 Infections. *Am J Trop Med Hyg.* 2020;103(2):561-63. DOI:10.4269/ajtmh.20-0473
- 292 [14] Sa-Ngiamsumtorn K, Suksatu A, Pewkliang Y, Thongsri P, Kanjanasirirat P,  
293 Manopwisedjaroen S, et al. Anti-SARS-CoV-2 Activity of *Andrographis paniculata*  
294 extract and its major component andrographolide in human lung epithelial cells and  
295 cytotoxicity evaluation in major organ cell representatives. *J Nat Prod.* 2021;84:1261-  
296 270. DOI:10.1021/acs.jnatprod.0c01324.
- 297 [15] Shi TH, Huang YL, Chen CC, Pi WC, Hsu YL, Lo LC, Chen WY, Fu SL, Lin CH.  
298 Andrographolide and its fluorescent derivative inhibit the main proteases of 2019-  
299 nCoV and SARS-CoV through covalent linkage. *Biochem Biophys Res Commun*  
300 2020 533: 467-73. DOI:10.1016/j.bbrc.2020.08.086.
- 301 [16] Stringer D, Braude P, Myint PK, Evans L, Collins JT, Verduri A, et al.; COPE Study  
302 Collaborators. The role of C-reactive protein as a prognostic marker in COVID-19.  
303 *Int J Epidemiol.* 2021;50:420-29. DOI:10.1093/ije/dyab012.
- 304 [17] Suriyo T, Pholphana N, Ungtrakul T, Rangkadilok N, Panomvana D, Thiantanawat  
305 A, et al. Clinical parameters following multiple oral dose administration of a  
306 standardized *Andrographis paniculata* capsule in healthy Thai subjects. *Planta*  
307 *Med.* 2017;83(9):778-89. doi: 10.1055/s-0043-104382.
- 308 [18] Thamlikitkul V, Dechatiwongse T, Theerapong S, Chantrakul C, Boonroj P, Punkrut  
309 W, et al. Efficacy of *Andrographis paniculata*, Nees for pharyngotonsillitis in adults.  
310 *J Med Assoc Thai.*1991;74:437-42.

- 311 [19] The State Pharmacopoeia Commission of the People's Republic of China.  
312 Pharmacopoeia of the People's Republic of China 2015. *Andrographis Herba*.  
313 Beijing, China: China Medical Science Press; 2015.
- 314 [20] Tsang R, Colley L, Lynd LD. Inadequate statistical power to detect clinically  
315 significant differences in adverse event rates in randomized controlled trials, *J Clin*  
316 *Epidemiol*, 2009; 62(6): 609-16. <https://doi.org/10.1016/j.jclinepi.2008.08.005>.
- 317 [21] van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, et al.  
318 COVID-19: immunopathology, pathophysiological mechanisms, and treatment  
319 options. *J Pathol*. 2021;254(4):307-31. DOI: 10.1002/path.5642.
- 320 [22] Wang L. C-reactive protein levels in the early stage of COVID-19. *Med Mal Infect*.  
321 2020; 50:332-34. DOI:10.1016/j.medmal.2020.03.007.
- 322 [23] WHO Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/> (Accessed: 13  
323 June 2021).
- 324 [24] Worakunphanich W, Thavorncharoensap M, Youngkong S, Thadanipon K,  
325 Thakkestian A. Safety of *Andrographis paniculata*: A systematic review and meta-  
326 analysis. *Pharmacoepidemiol Drug Saf*. 2021;30:727-39. DOI:10.1002/pds.5190.
- 327 [25] World Health Organisation. Vitamin and Mineral Information System. C-reactive  
328 protein concentrations as a marker of inflammation or infection for interpreting  
329 biomarkers of micronutrient status. WHO/NMH/NHD/EPG/14.7 (Accessed: 13 June  
330 2021)
- 331 [26] Wu Z. and McGoogan JM. Characteristics of and important lessons from the  
332 coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of

333 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA.

334 2020; 323:1239-242. DOI: 10.1001/jama.2020.2648.

335 [27] Zhang XY, Lv L, Zhou YL, Xie LD, Xu Q, Zou XF, et al. Efficacy and safety of

336 Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-

337 label and randomized controlled trial. Phytother Res. 2021; 12:10.1002/ptr.7141.

338 DOI: 10.1002/ptr.7141.

339

340



341 **Table 1** Baseline characteristics of patients who received *Andrographis paniculata* extract  
 342 (AP extract) or placebo

| Characteristics                                     | AP extract<br>(n=29) | Placebo<br>(n=28) | <i>p</i> -value |
|---|----------------------|-------------------|-----------------|
| Age (years), mean ± SD                              | 39.3 ± 11.4          | 39.4 ± 11.6       | 0.949           |
| Male, n (%)   | 12(41.4)             | 11 (39.3)         | 0.870           |
| BMI (kg/m <sup>2</sup> ), n (%)                     |                      |                   |                 |
| Underweight or normal weight                        | 19 (65.5)            | 15 (53.6)         | 0.684           |
| Overweight (BMI 25-29.9 kg/m <sup>2</sup> )         | 7 (24.1)             | 9 (32.1)          |                 |
| Moderate Obesity (BMI ≥ 30-34.9 kg/m <sup>2</sup> ) | 3 (10.3)             | 4 (14.3)          |                 |
| Severe Obesity (BMI ≥ 35 kg/m <sup>2</sup> )        | 0 (0.0)              | 0 (0.0)           |                 |
| CRP levels on hospital admission, n (%)             |                      |                   |                 |
| ≤5 mg/L   | 24 (82.8)            | 22 (78.6)         | 0.495           |
| >5-10 mg/L  | 5 (17.2)             | 4 (14.3)          |                 |
| >10-18 mg/L   | 0 (0.0)              | 2* (7.1)          |                 |

343 BMI = body mass index, CRP = C-reactive protein

344 \*One patient with rising CRP levels developed pneumonia, the other with steady CRP  
 345 levels did not.

346

347 **Table 2** The study outcomes in the groups of patients who received *Andrographis*  
348 *paniculata* extract (AP extract) or placebo.

| Outcomes                              | AP extract<br>(n=29) | Placebo<br>(n=28) | <i>p</i> -value |
|---------------------------------------|----------------------|-------------------|-----------------|
| Pneumonia, n (%)                      | 0 (0.0)              | 3 (10.7)          | 0.112           |
| Positive SARS-CoV-2 on Day 5**, n (%) | 10 (34.5)            | 16 (57.1)         | 0.086           |
| CRP >10mg/L on Day 5**, n (%)         | 0 (0.0)              | 5* (17.9)         | 0.023           |

349 CRP = C-reactive protein

350 \*3 patients developed pneumonia

351 \*\*Day 5 of clinical trial